JP2024528489A5 - - Google Patents
Info
- Publication number
- JP2024528489A5 JP2024528489A5 JP2023579476A JP2023579476A JP2024528489A5 JP 2024528489 A5 JP2024528489 A5 JP 2024528489A5 JP 2023579476 A JP2023579476 A JP 2023579476A JP 2023579476 A JP2023579476 A JP 2023579476A JP 2024528489 A5 JP2024528489 A5 JP 2024528489A5
- Authority
- JP
- Japan
- Prior art keywords
- hrd
- features
- genome
- positive
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215281P | 2021-06-25 | 2021-06-25 | |
| US63/215,281 | 2021-06-25 | ||
| PCT/US2022/073167 WO2022272310A1 (en) | 2021-06-25 | 2022-06-24 | System and method of classifying homologous repair deficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528489A JP2024528489A (ja) | 2024-07-30 |
| JP2024528489A5 true JP2024528489A5 (enExample) | 2025-06-19 |
Family
ID=84545873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579476A Pending JP2024528489A (ja) | 2021-06-25 | 2022-06-24 | 相同修復欠損を分類するシステムおよび方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230140123A1 (enExample) |
| EP (1) | EP4360094A4 (enExample) |
| JP (1) | JP2024528489A (enExample) |
| CN (1) | CN117561572A (enExample) |
| AU (1) | AU2022299105A1 (enExample) |
| TW (1) | TW202317774A (enExample) |
| WO (1) | WO2022272310A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260080973A1 (en) * | 2022-08-30 | 2026-03-19 | Foundation Medicine, Inc. | Systems and methods for classifying and treating homologous repair deficiency cancers |
| WO2024077041A2 (en) * | 2022-10-05 | 2024-04-11 | Foundation Medicine, Inc. | Methods and systems for identifying copy number signatures |
| CN116451070B (zh) * | 2023-03-17 | 2025-12-19 | 南京康尼机电股份有限公司 | 基于多分辨率窗口的轨道车门系统异常判别方法及系统 |
| AU2024264089A1 (en) * | 2023-04-28 | 2025-10-02 | Institut Curie | Methods for diagnosing a homologous recombination deficiency in human tumors |
| CN116312781B (zh) * | 2023-05-17 | 2023-08-18 | 普瑞基准科技（北京）有限公司 | 一种基于机器学习的基因组不稳定性评估方法及系统 |
| CN117011615B (zh) * | 2023-09-15 | 2025-12-19 | 湖南自兴智慧医疗科技有限公司 | 基于生成式模型数据增广的微核血细胞识别系统 |
| WO2025217185A1 (en) * | 2024-04-09 | 2025-10-16 | Foundation Medicine, Inc. | Parp inhibitors for the treatment of advanced prostate cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| US11348661B2 (en) * | 2018-05-14 | 2022-05-31 | Tempus Labs, Inc. | Predicting total nucleic acid yield and dissection boundaries for histology slides |
| US10975445B2 (en) * | 2019-02-12 | 2021-04-13 | Tempus Labs, Inc. | Integrated machine-learning framework to estimate homologous recombination deficiency |
| ES2989374T3 (es) * | 2019-12-10 | 2024-11-26 | Tempus Ai Inc | Sistemas y procedimientos para predecir el estado de deficiencia de recombinación homóloga de una muestra |
-
2022
- 2022-06-24 TW TW111123648A patent/TW202317774A/zh unknown
- 2022-06-24 AU AU2022299105A patent/AU2022299105A1/en active Pending
- 2022-06-24 EP EP22829531.7A patent/EP4360094A4/en active Pending
- 2022-06-24 CN CN202280043825.4A patent/CN117561572A/zh active Pending
- 2022-06-24 JP JP2023579476A patent/JP2024528489A/ja active Pending
- 2022-06-24 WO PCT/US2022/073167 patent/WO2022272310A1/en not_active Ceased
- 2022-08-30 US US17/899,470 patent/US20230140123A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024528489A5 (enExample) | ||
| McCreery et al. | Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers | |
| Pomerantz et al. | The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer | |
| Morrissy et al. | Divergent clonal selection dominates medulloblastoma at recurrence | |
| Kage et al. | Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing | |
| JP7224185B2 (ja) | Ｄｎａサンプルを特徴付ける方法 | |
| Kazandjian et al. | Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients | |
| US20210292845A1 (en) | Identifying methylation patterns that discriminate or indicate a cancer condition | |
| Schramm et al. | Next‐generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN‐amplified neuroblastoma | |
| US20200190594A1 (en) | Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer | |
| JP2017512491A5 (enExample) | ||
| Zhao et al. | EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis | |
| Lee et al. | Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment | |
| Burr et al. | Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors | |
| Bendall et al. | Specific human endogenous retroviruses predict metastatic potential in uveal melanoma | |
| US20240136017A1 (en) | Methods for the non-invasive detection and monitoring of therapeutic nucleic acid constructs | |
| TW201926094A (zh) | 三陰性乳癌的次分類及方法 | |
| Albitar et al. | Homologous recombination abnormalities associated with BRCA1/2 mutations as predicted by machine learning of targeted next-generation sequencing data | |
| Gunnarsson et al. | Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies | |
| Zhao et al. | Longitudinal profiling of circulating tumor DNA reveals the evolutionary dynamics of metastatic prostate cancer during serial therapy | |
| Shi et al. | Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer | |
| JP2025541235A (ja) | 患者特異的パネルを設計する技術及び微小残存病変を検出するためのその使用方法 | |
| Cho et al. | Risk stratification of childhood medulloblastoma using integrated diagnosis: discrepancies with clinical risk stratification | |
| US20180357368A1 (en) | Integrative panomic approach to pharmacogenomics screening | |
| KR20200044123A (ko) | 암 환자에서의 향상된 정밀도를 위한 포괄적 게놈 트랜스크립톰 종양-정상 유전자 패널 분석 (comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with cancer) |